[PDF][PDF] 交界可切除和局部进展期胰腺癌行新辅助化疗的疗效分析
商阳阳， 陶俊宇， 杨佳丽， 郭诗翔 - 中国普通外科杂志, 2023 - zpwz.net
摘要背景与目的: 胰腺癌是一种高致死率的消化道恶性肿瘤, 仅有大约20%
患者可接受根治性手术切除, 5 年存活率不到6%. 目前, 胰腺癌的治疗策略已从传统以手术切除 …
患者可接受根治性手术切除, 5 年存活率不到6%. 目前, 胰腺癌的治疗策略已从传统以手术切除 …
Outcomes of patients with borderline resectable pancreatic cancer treated with combination chemotherapy
S Templeton, M Moser, C Wall, J Shaw… - Journal of …, 2021 - Springer
Background Patients with borderline resectable pancreatic cancer are at high risk of
incomplete resection with upfront surgery. Currently, no standard induction chemotherapy …
incomplete resection with upfront surgery. Currently, no standard induction chemotherapy …
白蛋白结合型紫杉醇联合吉西他滨治疗进展期胰腺癌临床效果的Meta 分析.
王芸， 张耕源， 罗长江， 杨含腾 - Journal of Clinical …, 2019 - search.ebscohost.com
王芸1 ,张耕源2 ,罗长江2 ,杨含腾 Page 1 白蛋白结合型紫杉醇联合吉西他滨治疗进展期胰腺癌
临床效果的meta 分析 王芸1 ,张耕源2 ,罗长江2 ,杨含腾2 (1 甘肃省武威肿瘤医院化疗科,甘肃武威 …
临床效果的meta 分析 王芸1 ,张耕源2 ,罗长江2 ,杨含腾2 (1 甘肃省武威肿瘤医院化疗科,甘肃武威 …
[HTML][HTML] Splenic artery transposition for hepatic arterial reconstruction in conversion surgery of an initially unresectable, locally advanced pancreatic cancer after …
H Tanaka, H Imai, T Higashi, K Murase… - International Journal of …, 2021 - Elsevier
Introduction and importance Recent advances in chemotherapy and chemoradiotherapy
allow performance of conversion surgery by improving tumor shrinkage in select patients …
allow performance of conversion surgery by improving tumor shrinkage in select patients …
Neoadjuvant therapy: when should it be used for pancreatic cancer?
KN Kelly, FI Macedo, NB Merchant - Advances in Surgery, 2020 - advancessurgery.com
Neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel are promising therapies and may
be associated with improved oncologic outcomes compared with single-agent regimens or …
be associated with improved oncologic outcomes compared with single-agent regimens or …
Delayed gastric emptying does not influence cancer-specific survival after pancreatoduodenectomy for pancreatic ductal adenocarcinoma
C Pillny, J Teschke, J Enderes, S Manekeller… - Journal of Clinical …, 2022 - mdpi.com
Background: Delayed gastric emptying (DGE) remains the most frequent complication
following pancreatoduodenectomy (PD). The present study investigates the influence of …
following pancreatoduodenectomy (PD). The present study investigates the influence of …
A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab‑paclitaxel for resectable pancreatic cancer
H Tajima, I Makino, R Gabata… - Molecular and …, 2021 - spandidos-publications.com
Neoadjuvant chemotherapy (NAC) has become a standard treatment for borderline
resectable pancreatic ductal adenocarcinoma (PDAC). The present study examined the …
resectable pancreatic ductal adenocarcinoma (PDAC). The present study examined the …
Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
KV Trinh, DA Fischer, TB Gardner, KD Smith - Frontiers in Oncology, 2020 - frontiersin.org
Introduction: Neoadjuvant therapy is increasingly being used for localized pancreatic
adenocarcinoma. While there is evidence supporting neoadjuvant systemic chemotherapy …
adenocarcinoma. While there is evidence supporting neoadjuvant systemic chemotherapy …
Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
JH Choi, MK Kim, SH Lee, JW Park, N Park… - Frontiers in …, 2022 - frontiersin.org
Background The complete resection rate of pancreatic cancer has increased because of the
advent of efficacious first-line treatments for unresectable pancreatic cancer. Still, strategies …
advent of efficacious first-line treatments for unresectable pancreatic cancer. Still, strategies …
联合腹腔干切除的全胰十二指肠切除术一例报道并文献复习
孟令威， 蔡云强， 李永彬， 蔡合， 徐均， 彭兵 - 肝胆胰外科杂志, 2021 - gdy.qk.wmu.edu.cn
目的总结联合腹腔干切除的全胰十二指肠切除术治疗局部进展期胰颈腺癌的临床经验.
方法回顾性分析四川大学华西医院上锦医院肝胆胰微创中心2018 年12 月1 …
方法回顾性分析四川大学华西医院上锦医院肝胆胰微创中心2018 年12 月1 …